Immunogen, Inc. (NASDAQ: IMGN) reported Q4 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $3.83 million versus the consensus estimate of $3.44 million.

For earnings history and earnings-related data on Immunogen, Inc. (IMGN) click here.

Earnings